Microchip implant could personalize skin cancer treatment
NCT ID NCT06782399
First seen May 19, 2026 · Last updated May 25, 2026 · Updated 1 time
Summary
This study tests a small implantable device that delivers tiny amounts of different cancer drugs directly into skin cancer lesions. The goal is to see which drug kills the most cancer cells, helping doctors choose the best treatment for each patient. About 25 adults with squamous cell skin cancer will take part. The device is removed after a short time, and the tissue is analyzed. This is an early-phase study focused on feasibility and safety, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE SKIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Insitute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.